drugset / Trial / NCT04810676

A Clinical Trial to Evaluate the Pharmacokinetic Profiles and Safety of CKD-383.

NCT04810676

Phase 1 Completed 27 enrolled Chong Kun Dang Pharmaceutical
RandomizedCrossoverOpen-labelTreatment

Summary

A clinical trial to evaluate the pharmacokinetic profiles and safety of CKD-383.

Timeline

Start
2021-04-16
Primary completion
2021-05-20
Completion
2021-05-26

Drugs

EvaluationDrugModalityDoseRoute
Subject CKD-383 Unknown Oral
Subject D150 Unknown Oral
Subject D745 Unknown Oral
Subject Lobeglitazone Small molecule Oral